Nuwellis, Inc. has received a new U.S. patent for its advanced safety technology used in pediatric blood filtration systems. The United States Patent and Trademark Office (USPTO) issued a notice of allowance for the company’s latest invention that strengthens the safety features of its Vivian Pediatric Continuous Renal Replacement Therapy (CRRT) system.
The new patent covers an intelligent clamp system that enhances patient safety during blood filtration. It automatically adjusts the clamping force based on environmental conditions and tubing characteristics. The system can also recondition tubing under specific thermal settings and includes thermal insulation to maintain consistent performance.
Nuwellis designed this innovation to improve reliability in treating infants and small children who require extracorporeal blood therapy. Pediatric patients are more vulnerable to blood volume imbalances, pressure changes, and tubing failures. The new clamp technology aims to minimize these risks and deliver precise, safe therapy for children weighing between 2.5 and 20 kilograms.
The company said the new patent builds on its expanding intellectual property portfolio in pediatric blood purification. In September 2025, Nuwellis received another patent for a hemolysis detection system that monitors blood damage during filtration. Together, these technologies strengthen the safety framework of the Vivian system.
The Vivian Pediatric System remains an investigational device and is not yet available for commercial use. Nuwellis continues to refine the system as part of its mission to advance fluid management and kidney care for critical pediatric patients.
Chief Technology Officer Dan Rose highlighted that the new patent demonstrates Nuwellis’s focus on safety and innovation. He said the company is committed to developing technologies that support clinicians and protect the most delicate patient groups.
Nuwellis’s previous studies have shown encouraging results in pediatric care. Its earlier Aquadex system achieved a 92% survival rate in children with acute kidney injury, underscoring the company’s expertise in pediatric ultrafiltration technology.
The new patent is expected to enhance Nuwellis’s competitive position in the growing pediatric renal care market. It also reinforces the company’s strategy to expand its intellectual property base and protect its research-driven innovations.
With this milestone, Nuwellis continues to move closer to offering a fully developed pediatric blood filtration solution that prioritizes precision, safety, and clinical reliability.